Our reports provide an independent, expert view supported by robust and innovative data interrogation and analysis.

Refine Sector
Sub-Category
Clear
Publish Date
Clear
Region
Clear
Clear All
Sort by:
Frontier Pharma: Ophthalmology Therapeutics - Gene Therapies and First-in-Class Targets Offer Novel Treatments for Substantial Unmet Needs in a Pipeline Dominated by Angiogenic and Immune Signaling Drugs

Published: Oct-2017

The ophthalmologic therapy area encompasses a wide range of disorders affecting the eye and its supporting structures......

$6995
More Info
Frontier Pharma:Cancer Immunotherapies – First-in-Class Pipeline Dominated by Immunomodulators and PD-1 Like Targets

Published: Sep-2017

Cancer is a group of diseases that are defined by abnormal cell growth, local tissue invasion and eventual migration to.....

$6995
More Info
$6995
More Info
Frontier Pharma: Cardiovascular Disease – Diverse First-in-Class Molecular Targets to Bridge Unmet Needs in Pulmonary Hypertension, Heart Failure and Atherosclerosis

Published: Aug-2017

The cardiovascular disease (CVD) therapy area encompasses a range of different diseases and conditions affecting the heart.....

$6995
More Info
Frontier Pharma: Liver Cancer - Identifying and Commercializing First-in-Class Innovation

Published: Jun-2017

Globally, liver cancer is the sixth most common cancer, but its poor prognosis makes it the second leading cause of cancer-related.....

$6995
More Info
Frontier Pharma: Dermatology – Intracellular Signal Transducers and Cytokine Signaling Molecules Dominate Pipeline and First-in-Class Innovation

Published: Jun-2017

Dermatology is a highly diverse therapy area that deals with diseases of the skin, hair and nails. Over 3,000 distinct.....

$6995
More Info
Frontier Pharma: Alzheimer’s Disease and Associated Indications – Exceptional Level of First-in-Class Innovation within AD, and Diverse Range of Therapies in Development for Disorders Such as Anxiety and Depression

Published: May-2017

Alzheimer’s disease (AD), the most common form of dementia, is a progressive, neurodegenerative and currently incurable.....

$6995
More Info
Frontier Pharma: First-in-Class Innovation in Hematological Cancers – Cytokine Signaling and Kinase Targeted Immunotherapies Dominate a Large and Highly Versatile Pipeline

Published: May-2017

The American Cancer Society (ACS) predicts that in 2017 there will be almost 173,000 new cases of leukemia, lymphoma and.....

$6995
More Info
20%
off
Frontier Pharma: Head and Neck Cancer – Immunotherapies and Signal Transduction Inhibitors Dominate First-in-Class Innovation

Published: Mar-2017

Head and neck squamous cell carcinoma is the sixth most common cancer, and its incidence is rising. The term head and.....

Offer expires on Oct 27 2017

$6995
$5596
More Info
20%
off
Frontier Pharma: Fatty Liver Disease – High Degree of First-in-Class Innovation, Dominated by Nuclear Receptor-Targeting NASH Products

Published: Mar-2017

Fatty liver disease (FLD) comprises a spectrum of chronic liver disorders characterized by excessive lipid accumulation.....

Offer expires on Oct 27 2017

$6995
$5596
More Info
Sort by: